Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

F K Habib, M Ross, R Tate, G D Chisholm

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.
LanguageEnglish
Pages137-44
Number of pages8
JournalClinical Endocrinology
Volume46
Issue number2
DOIs
Publication statusPublished - 1997

Fingerprint

Cholestenone 5 alpha-Reductase
Finasteride
Prostatic Hyperplasia
Androgens
5-alpha Reductase Inhibitors
Prostate
Antigens
Therapeutics
Pharmaceutical Preparations

Keywords

  • 5-alpha reductase inhibitors
  • aged
  • androgens
  • androstenedione
  • dihydrotestosterone
  • double-blind method
  • finasteride
  • humans
  • prostate
  • prostate-specific antigen
  • prostatic hyperplasia
  • testosterone

Cite this

@article{332b1b1216c249b7b8e122818d1336c0,
title = "Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia",
abstract = "The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.",
keywords = "5-alpha reductase inhibitors, aged, androgens, androstenedione, dihydrotestosterone, double-blind method, finasteride, humans, prostate, prostate-specific antigen, prostatic hyperplasia, testosterone",
author = "Habib, {F K} and M Ross and R Tate and Chisholm, {G D}",
year = "1997",
doi = "10.1046/j.1365-2265.1997.950908.x",
language = "English",
volume = "46",
pages = "137--44",
journal = "Clinical Endocrinology",
issn = "0300-0664",
number = "2",

}

Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. / Habib, F K; Ross, M; Tate, R; Chisholm, G D.

In: Clinical Endocrinology, Vol. 46, No. 2, 1997, p. 137-44.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia

AU - Habib, F K

AU - Ross, M

AU - Tate, R

AU - Chisholm, G D

PY - 1997

Y1 - 1997

N2 - The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.

AB - The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.

KW - 5-alpha reductase inhibitors

KW - aged

KW - androgens

KW - androstenedione

KW - dihydrotestosterone

KW - double-blind method

KW - finasteride

KW - humans

KW - prostate

KW - prostate-specific antigen

KW - prostatic hyperplasia

KW - testosterone

U2 - 10.1046/j.1365-2265.1997.950908.x

DO - 10.1046/j.1365-2265.1997.950908.x

M3 - Article

VL - 46

SP - 137

EP - 144

JO - Clinical Endocrinology

T2 - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -